HER-2阳性乳腺癌新辅助治疗腋窝病理完全缓解的预测因素分析

目的:研究人类表皮生长因子受体2（human epidermal growth factor receptor 2，HER-2）阳性乳腺癌新辅助治疗腋窝病理完全缓解（axillary pathological complete response，apCR）的预测因素。方法:回顾性分析2017年1月至2019年12月四川省肿瘤医院乳腺外科中心经治的新辅助治疗HER-2阳性乳腺癌，分析临床病理特点与apCR的相关性。统计学分析使用SPSS 22.0统计学软件。计量资料使用最小值、最大值和中位数表示，计数和等级资料使用频数和百分比表示。单因素分析使用χ2检验或Fisher确切概率法，多因素分析使用二元Logistic回归分析。结果:本研究纳入94例HER-2阳性乳腺癌，总体apCR率为73.4%（69／94）。单因素分析显示，临床N0期（P=0.005）、激素受体状态阴性（P=0.008）、联合抗HER-2治疗（P<0.001）及达到乳房病理完全缓解（P=0.007）与高apCR率的相关性具有统计学意义。多因素分析显示，联合抗HER-2治疗（OR=4.77，95%CI:1.49～15.34，P=0.009）是高apCR率的独立预测因素。结论:联合抗HER-2治疗是HER-2阳性乳腺癌新辅助治疗apCR的独立预测因素。

Predictive factors of axillary pathological complete response in neoadjuvant-treated HER-2-positive breast cancer

Objective:To investigate the predictive factors of axillary pathological complete response(apCR)in human epidermal growth factor receptor 2(HER-2)-positive breast cancer treated with neoadjuvant treatment(NAT).Methods:Data of HER-2-positive breast cancer treated with NAT and radical surgery in the Breast Surgery Center of Sichuan Cancer Hospital from January 2017 to December 2019 was retrospectively reviewed.The Chi-square test or Fisher's exact test was conducted for univariate analyses,and Logistic regression analyses were performed for multivariate analyses.Statistical analyses were conducted using SPSS version 22.0.Results:Ninety-four HER-2-positive patients were included,and the overall apCR rate was 73.4%(69/94).Clinical N 0 stage(P=0.005),negative status of hormone receptor(P=0.008),anti-HER-2 therapy(P<0.001)and breast pathological complete response(P=0.007)were significantly associated with apCR in univariate analysis.Anti-HER-2 therapy(OR=4.77,95%CI:1.49~15.34,P=0.009)was independently associated with apCR in multivariate analysis.Conclusion:Anti-HER-2 therapy was an independent predictive factor for apCR in neoadjuvant-treated HER-2-positive breast cancer.